COOKIES USE We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics. +info
Cookies config
Necessary
The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_GRECAPTCHA
google.com
Own
provide antispam protection with the reCaptcha service
6 months
cc_cookie_accept
fidmag.org
Own
Usada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)
1 any
WEB_SESSION
fidmag.org
Own
Cookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.
al acabar la sessió
Analisys
Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.
Name
Proveedor
Propiedad
Finalidad
Caducidad
+info
_ga
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics
2 anys
_gat_gtag_UA_141706552_1
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: Tracking per part de google per google analytics
1 minut
_gid
Google Analytics
From third parties
Cookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds
2015International Journal of Neuropsychopharmacology
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.
Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A, Díaz-Caneja CM, Corripio I, Aguilar EJ, Bulbena A, Castro-Fornieles J, Vieta E, Lafuente A, Mas S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M
Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.
Abstract
The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice.Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period.The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001).These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.